Lanzhou, China --- The last two hepatotomies were performed by Director Yuntao Ma of the General Surgery Department of Gansu Provincial Hospital on January 22, 2022 with Toumai® Laparoscopic Surgical Robot (Toumai®) independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot®"), marking a successful end of the center's confirmatory clinical trial. Under the guidance of Hui Cai, President of Gansu Provincial Hospital ,Yuntao Ma, director of General Surgery and Yunjiu Gou, director of Thoracic Surgery, led a team to set a record of the highest single-center surgical volume in the clinical trial, and completed the first hepatotomy, the first radical gastrectomy and the first radical resection of pulmonary carcinoma with Chinese-developed robots, which fully testifies that the Chinese-developed laparoscopic surgical robot has the capability of multi-department large-scale clinical application and complex surgeries.

 Director Yuntao Ma and Director Yunjiu Gou commented after the operation, "Toumai^® has been integrated with the energy devices such as ultrasonic scalpel and high frequency electrotome, and the advanced technologies such as 3D imaging and tele-operation. It has shown excellent performance in clinical trials, and can provide a stable, efficient and accurate solution to the operation. With the approach of substitution with made-in-China products, the development of standardized training for clinicians, the R&D of supporting instruments and the polishing of surgical teams, the Chinese-developed robot-assisted surgery will be more widely applied in general surgery and thoracic surgery. We look forward to the early marketization of Toumai^®. We hope that the advanced robot technology independently developed by China can go down to all regions of the country and benefit more people with the high-quality and affordable surgical treatment resources.”

 Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®, said, "With the strong support of experts, the multi-disciplinary and multi-center confirmatory clinical enrollment of Toumai^® has been completed. It means that the Chinese-developed surgical robots can provide services to more patients and accelerate the process of substitution with Chinese-developed products. MicroPort® MedBot® hopes to provide hospitals and experts with more intelligent surgical solutions, and realize the initial goal to ‘Make Surgery Easier, Safer and Less Invasive!”